FDA NDA · NDA202814

LAMIVUDINE; ZIDOVUDINE

Sponsor: CIPLA LIMITED

APPLICATION

NDA202814

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET, FOR SUSPENSION

MARKETING STATUS

None (Tentative Approval)

Products

LAMIVUDINE; ZIDOVUDINENone (Tentative Approval)

LAMIVUDINE 30MG, ZIDOVUDINE 60MG · TABLET, FOR SUSPENSION · ORAL

2012-06-15Type 5 - New Formulation or New Manufacturer · Original · standard — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.